---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021658"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:59:18.404479+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Geron reports Q4/FY2023 results; cash $378M, PDUFA June 16, 2024 for imetelstat

## Summary
- Cash, cash equivalents and marketable securities of $378.1M as of Dec 31, 2023; cash runway into Q3 2025.
- FDA PDUFA action date June 16, 2024 for imetelstat NDA in transfusion-dependent LR-MDS; ODAC meeting March 14, 2024.
- Total operating expenses FY2023: $194.1M (R&D $125M, G&A $69.1M); FY2024 guidance $270-280M.
- Phase 3 IMpactMF for myelofibrosis achieved 50% enrollment; interim analysis expected H1 2025.
- Revenue minimal at $237,000 for FY2023; company plans to grow to ~270 employees by end of 2024 if approved.

## SEC filing metadata
- accession: 0000950170-24-021658
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017024021658/0000950170-24-021658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017024021658/gern-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021658
- JSON: https://secwatch.observer/filing/0000950170-24-021658.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021658.txt

## Key facts
- Earnings Releases
  GERON CORP reported the fourth quarter and full year 2023 results: revenue $23,000 and $237,000, respectively.
  - Period: the fourth quarter and full year 2023
  - Revenue: $23,000 and $237,000, respectively
  - Result: reported results
  source text: loan facility, will be sufficient to fund its projected operating expenses into the third quarter of 2025. Revenues for the three and twelve months ended December 31, 2023, were $23,000 and $237,000, respectively, compared to $103,000 and $596,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of
  evidence_url: https://www.sec.gov/Archives/edgar/data/886744/000095017024021658/0000950170-24-021658-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.